Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer
| Autor: | Ning Shao, Shi Ge Zhang, Ye Wu, Jiu Ling Wang, Ning Han Feng, Di Qiao, Yi Ding, Yang Wang, Xiang Xiang Zhang, Wen Yu Jiang |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty business.industry medicine.medical_treatment Hazard ratio Peripheral edema Immunotherapy Pharmacology medicine.disease law.invention Clinical trial Prostate cancer Randomized controlled trial law Internal medicine medicine Chills medicine.symptom business Endothelin receptor |
| Zdroj: | International Journal of Cancer. 133:1743-1750 |
| ISSN: | 0020-7136 |
| DOI: | 10.1002/ijc.28162 |
| Popis: | Recently, novel therapies of prostate cancer, such as immunotherapy, endothelin receptor antagonists, novel androgen receptor antagonist and novel taxanes, and others have been introduced into clinical practice. This study was performed to summarize these results of immunotherapy and endothelin receptor antagonists in the treatment of castration-resistant prostate cancer (CRPC) and derive a more precise estimation of their effect on future treatment. The PubMed database, references of published trials, and review articles were searched. Two reviewers independently extracted data of these trials. We used hazard ratios (HRs) to assess the effects on overall survival (OS), progression-free survival (PFS), or time to disease progression (TTP), and relative risk (RR) for the different types of toxicity. In addition, 95% confidence intervals (CIs) give a sense of the precision of the estimate. Nine randomized controlled trials were ultimately identified. The pooled HR showed that immunotherapy could prolong OS significantly in patients with CRPC compared to placebo (HR = 0.70, 95% CI: 0.58–0.83, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text